171 related articles for article (PubMed ID: 38057698)
21. Establish six-gene prognostic model for glioblastoma based on multi-omics data of TCGA database.
Lei CG; Jia XY; Sun WJ
Yi Chuan; 2021 Jul; 43(7):665-679. PubMed ID: 34284982
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
23. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
Long S; Li M; Liu J; Yang Y; Li G
Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
[TBL] [Abstract][Full Text] [Related]
24. Construction of an immune-related gene signature for the prognosis and diagnosis of glioblastoma multiforme.
Yu Z; Yang H; Song K; Fu P; Shen J; Xu M; Xu H
Front Oncol; 2022; 12():938679. PubMed ID: 35982954
[TBL] [Abstract][Full Text] [Related]
25. Characterization of ferroptosis signature to evaluate the predict prognosis and immunotherapy in glioblastoma.
Zhu X; Zhou Y; Ou Y; Cheng Z; Han D; Chu Z; Pan S
Aging (Albany NY); 2021 Jul; 13(13):17655-17672. PubMed ID: 34244461
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF; Piazzini F; Caruso FP; Marzani F; Solmonese L; Bello E; Celesti F; Costa MC; Noviello T; Mortarini R; Anichini A; Ceccarelli M; Coral S; Di Giacomo AM; Maio M; Covre A;
J Transl Med; 2024 Mar; 22(1):223. PubMed ID: 38429759
[TBL] [Abstract][Full Text] [Related]
27. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
28. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
Front Immunol; 2022; 13():819515. PubMed ID: 35251000
[TBL] [Abstract][Full Text] [Related]
29. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
30. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
31. ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.
Lailler C; Louandre C; Morisse MC; Lhossein T; Godin C; Lottin M; Constans JM; Chauffert B; Galmiche A; Saidak Z
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31467175
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the sodium pump subunit ATP1A3 in glioma patients: Potential value in prognostic prediction and immunotherapy.
Lan YL; Zou S; Qin B; Zhu X
Int Immunopharmacol; 2024 May; 133():112045. PubMed ID: 38615384
[TBL] [Abstract][Full Text] [Related]
33. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis.
Chen X; Pan Y; Yan M; Bao G; Sun X
Mol Med Rep; 2020 Aug; 22(2):859-869. PubMed ID: 32467990
[TBL] [Abstract][Full Text] [Related]
34. Exploring the prognostic value of HK3 and its association with immune infiltration in glioblastoma multiforme.
Yang Y; Fu X; Liu R; Yan L; Yang Y
Front Genet; 2022; 13():1033572. PubMed ID: 36712881
[No Abstract] [Full Text] [Related]
35. Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner.
Lindemann C; Marschall V; Weigert A; Klingebiel T; Fulda S
Neoplasia; 2015 Jun; 17(6):481-9. PubMed ID: 26152356
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme.
Ye Y; Zhong W; Qian J; Zhang J; Xu T; Han R; Han J; Wang C; Song L; Zeng X; Wang H
Front Cell Dev Biol; 2023; 11():1042490. PubMed ID: 36711038
[No Abstract] [Full Text] [Related]
37. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.
Cai J; Zhang W; Yang P; Wang Y; Li M; Zhang C; Wang Z; Hu H; Liu Y; Li Q; Wen J; Sun B; Wang X; Jiang T; Jiang C
PLoS One; 2015; 10(5):e0126022. PubMed ID: 25978454
[TBL] [Abstract][Full Text] [Related]
38. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
39. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment.
Jia D; Li S; Li D; Xue H; Yang D; Liu Y
Aging (Albany NY); 2018 Apr; 10(4):592-605. PubMed ID: 29676997
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson's disease.
Zhao S; Chi H; Yang Q; Chen S; Wu C; Lai G; Xu K; Su K; Luo H; Peng G; Xia Z; Cheng C; Lu P
Front Immunol; 2023; 14():1090040. PubMed ID: 36825022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]